{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-026349","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.449380+00:00","generated_at":"2026-06-18T22:27:32.386574+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bicycle Therapeutics reports FY2022 net loss of $112.7M; cash $339.2M, runway into 2025","bullets":["Net loss of $30.0M in Q4 2022 ($1.01/share) and $112.7M for FY2022 ($3.80/share), vs $18.0M and $66.8M in prior year.","Cash and equivalents $339.2M at Dec 31, 2022, down from $438.7M; expected to fund operations into 2025.","R&D expenses rose to $81.6M in FY2022 from $44.9M, driven by clinical programs for BT5528, BT8009, and TICA platform.","BT8009 granted FDA Fast Track Designation for urothelial cancer; Phase II expansion initiated with RP2Ds established.","BT5528 continues in dose expansion; BT7480 in dose escalation; pipeline updates expected later in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-026349","json":"https://secwatch.observer/filing/0001104659-23-026349.json","markdown":"https://secwatch.observer/filing/0001104659-23-026349.md","text":"https://secwatch.observer/filing/0001104659-23-026349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923026349/0001104659-23-026349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923026349/tm237668d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:27:32.386574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4bd1c1a153ae0d3cc0ee3568c0d6fef014ba3a19","claim":"BICYCLE THERAPEUTICS PLC reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $30.0 million, or $(1.01) basic and diluted net loss per share, for the three months ended December 31, 202, EPS $(1.01) basic and diluted net loss per share.","evidence_excerpt":"On February 28, 2023, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter and the year ended December 31, 2022 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923026349/0001104659-23-026349-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Net income","value":"Net loss was $30.0 million, or $(1.01) basic and diluted net loss per share, for the three months ended December 31, 202"},{"label":"EPS","value":"$(1.01) basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}